Xoma Ltd (XOMA) 3.41 $XOMA
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.03 (unch), CLDX: 20.97 (+0.53), JUNO: 40.52 (+0.18), XOMA: 3.41 (-0.01), PDLI: 7.28 (+0.03)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 4:36PM CST
SCCO: 30.43 (+0.30), FLML: 14.15 (+0.15), GDP: 3.58 (+0.29), PBF: 30.18 (+0.27), DGAZ: 7.10 (-0.49), IAG: 2.23 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ALKS: 71.40 (-1.89), XOMA: 3.41 (-0.01)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 117.74 (-1.77), CODI: 16.61 (+0.03), MILL: 2.07 (+0.09), NRX: 6.67 (-0.14), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), LVS: 60.43 (+1.71), SPB: 94.05 (+0.80), QVCA: 29.47 (+0.42), LMCA: 37.97 (+0.06), BGH: 21.24 (+0.06), SIX: 45.11 (-0.05), AGIO: 118.55 (+0.11), XOMA: 3.41 (-0.01), JGV: 12.93 (+0.09)
XOMA Corp. (XOMA) in Focus: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:37AM CST
XOMA Corporation (XOMA) was a big mover last session, as the company saw its shares rise a little above 9% on the day.
AFFX: 11.45 (+0.02), XOMA: 3.41 (-0.01)
Why XOMA Corp. Stock Plunged 37% in December
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 05, 1:03PM CST
What: Shares of XOMA , a clinical-stage biopharmaceutical company focused on developing therapies to primarily treat metabolic, inflammatory, and infectious diseases, were absolutely decimated in December, losing 37% of their value, according to...
PJC: 55.10 (-1.61), XOMA: 3.41 (-0.01)
Stock to Watch: XOMA Up 8.9% (XOMA)
Comtex SmarTrend(R) - Mon Jan 05, 12:41PM CST
XOMA (NASDAQ:XOMA) is one of today's best performing low-priced stocks, up 8.9% to $3.86 on 1.0x average daily volume. XOMA has traded 3.6 million shares thus far today, vs. average volume of 3.6 million shares per day. The stock has outperformed the Dow (8.9% to the Dow's -1.8%) and outperformed the S&P 500 (8.9% to the S&P's -1.8%) during today's trading.
XOMA: 3.41 (-0.01)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.47 (+0.01), TKMR: 21.45 (-0.22), ARNA: 4.55 (+0.02), DYAX: 15.00 (-0.16), XOMA: 3.41 (-0.01)
InsiderInsights.com Daily Round Up 12/30/14: XOMA, ECR, SNCR, AVK
InsiderInsights - at Seeking Alpha - Wed Dec 31, 10:49AM CST
BDSI: 14.92 (+0.93), ECR: 7.29 (+0.12), KFRC: 23.24 (+0.26), EVDY: 13.80 (-0.32), SAM: 303.26 (-0.97), AERI: 27.91 (+0.14), FUND: 7.47 (+0.05), RFMD: 16.59 (-0.35), AVK: 17.07 (-0.01), SNCR: 43.89 (+1.06), FTEK: 3.31 (+0.01), CAS: 6.14 (-0.01), COB: 10.25 (+0.18), XOMA: 3.41 (-0.01), CRM: 62.85 (+1.59)
XOMA (XOMA) Is Today's Dead Cat Bounce Stock
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a "dead cat bounce" (down big yesterday but up big today) candidate
XOMA: 3.41 (-0.01)
Investors look to Lighten Up on Shares of XOMA, Shares Down 7.3% (XOMA)
Comtex SmarTrend(R) - Tue Dec 23, 11:35AM CST
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 7.3% to $3.67 on 1.1x average daily volume. XOMA has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-6.4% to the Dow's 0.5%) and underperformed the S&P 500 (-6.4% to the S&P's 0.2%) during today's trading.
XOMA: 3.41 (-0.01)
Acne Vulgaris - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/86w8nv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Advancell - Allergan - AndroScience - AntiCancer - Ausio Pharmaceuticals - Biomar Microbial - Boehringer Ingelheim - Braintree Laboratories - Celtaxsys - Cosmo Pharmaceuticals - Cutanea Life Sciences - Delenex Therapeutics - Deltanoid Pharmaceuticals - Dermira - ELORAC - Ensoltek - Foamix - Galderma - GlaxoSmithKline - Kasiak Research - Maruho - OrigImm - Phosphagenics - Photocure - Provectus Biopharmaceuticals - RestorGenex Corporation - Thesan Pharmaceuticals - Toyama Chemical - Valeant Pharmaceuticals International - XBiotech USA - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/86...e_vulgaris
PVCT: 0.79 (-0.02), AGN: 229.49 (+1.87), GSK: 47.94 (+1.99), XOMA: 3.41 (-0.01), VRX.TO: 207.95 (-1.47)
InsiderInsights.com Daily Round Up 12/16/14: XOMA, NS, TEP, RES
InsiderInsights - at Seeking Alpha - Wed Dec 17, 2:27PM CST
RH: 86.77 (-1.55), VRTX: 113.66 (+4.03), RES: 13.36 (+0.93), CCO: 9.46 (+0.07), HDS: 28.62 (+0.24), NS: 61.94 (-0.06), MFRM: 62.22 (-0.12), PCLN: 1,103.37 (+11.42), HERO: 0.92 (+0.02), TEP: 48.97 (+0.52), LC: 21.95 (+0.48), WIW: 11.29 (unch), FII: 35.09 (+0.20), HMTV: 13.25 (+0.23), DYN: 28.39 (+0.01), TWTR: 48.50 (+0.55), FOXF: 16.14 (+0.31), YUM: 74.69 (-0.11), WIA: 11.49 (-0.03), XOMA: 3.41 (-0.01)
Xoma prices offering
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 8:47AM CST
XOMA: 3.41 (-0.01)
XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants
GlobeNewswire - Tue Dec 09, 8:12AM CST
XOMA Corporation (Nasdaq:XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. The shares and warrants will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3. XOMA anticipates its aggregate proceeds from the offering will be approximately $37.7 million, not including any future proceeds from the exercise of the warrants, after deducting the placement agent's discount and estimated offering expenses payable by XOMA. The offering is expected to close on or about December 12, 2014, subject to customary closing conditions.
XOMA: 3.41 (-0.01)
InsiderInsights.com Daily Round Up 12/4/14: GPRO, XOMA, PSEC, KMT
InsiderInsights - at Seeking Alpha - Fri Dec 05, 5:22PM CST
GPRO: 45.27 (-0.02), CLR: 47.36 (+0.74), PATK: 46.96 (+0.45), JONE: 10.18 (+0.18), RL: 135.20 (-0.60), PRSS: 2.95 (-0.08), KMT: 35.44 (+0.86), TSRA: 39.27 (-0.05), WDAY: 91.84 (+0.67), DYN: 28.39 (+0.01), WRLD: 78.79 (-0.21), OC: 38.72 (+0.19), DATA: 99.90 (+1.40), SFXE: 3.49 (+0.01), PSEC: 8.67 (+0.07), REPH: 3.13 (-0.12), XOMA: 3.41 (-0.01)
Strong On High Relative Volume: XOMA (XOMA)
at The Street - Fri Dec 05, 9:05AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a strong on high relative volume candidate
XOMA: 3.41 (-0.01)
XOMA sell-off continues
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 12:30PM CST
XOMA: 3.41 (-0.01)
XOMA Down 6.9%, Shares Slide into the Red (XOMA)
Comtex SmarTrend(R) - Wed Dec 03, 10:07AM CST
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 6.9% to $4.74 on 1.5x average daily volume. XOMA has traded 2.7 million shares thus far today, vs. average volume of 1.8 million shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.1%) and underperformed the S&P 500 (-6.9% to the S&P's 0.2%) during today's trading.
XOMA: 3.41 (-0.01)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.03 (unch), CLDX: 20.97 (+0.53), JUNO: 40.52 (+0.18), XOMA: 3.41 (-0.01), PDLI: 7.28 (+0.03)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 4:36PM CST
SCCO: 30.43 (+0.30), FLML: 14.15 (+0.15), GDP: 3.58 (+0.29), PBF: 30.18 (+0.27), DGAZ: 7.10 (-0.49), IAG: 2.23 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ALKS: 71.40 (-1.89), XOMA: 3.41 (-0.01)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 117.74 (-1.77), CODI: 16.61 (+0.03), MILL: 2.07 (+0.09), NRX: 6.67 (-0.14), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), LVS: 60.43 (+1.71), SPB: 94.05 (+0.80), QVCA: 29.47 (+0.42), LMCA: 37.97 (+0.06), BGH: 21.24 (+0.06), SIX: 45.11 (-0.05), AGIO: 118.55 (+0.11), XOMA: 3.41 (-0.01), JGV: 12.93 (+0.09)
XOMA Corp. (XOMA) in Focus: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:37AM CST
XOMA Corporation (XOMA) was a big mover last session, as the company saw its shares rise a little above 9% on the day.
AFFX: 11.45 (+0.02), XOMA: 3.41 (-0.01)
Why XOMA Corp. Stock Plunged 37% in December
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 05, 1:03PM CST
What: Shares of XOMA , a clinical-stage biopharmaceutical company focused on developing therapies to primarily treat metabolic, inflammatory, and infectious diseases, were absolutely decimated in December, losing 37% of their value, according to...
PJC: 55.10 (-1.61), XOMA: 3.41 (-0.01)
Stock to Watch: XOMA Up 8.9% (XOMA)
Comtex SmarTrend(R) - Mon Jan 05, 12:41PM CST
XOMA (NASDAQ:XOMA) is one of today's best performing low-priced stocks, up 8.9% to $3.86 on 1.0x average daily volume. XOMA has traded 3.6 million shares thus far today, vs. average volume of 3.6 million shares per day. The stock has outperformed the Dow (8.9% to the Dow's -1.8%) and outperformed the S&P 500 (8.9% to the S&P's -1.8%) during today's trading.
XOMA: 3.41 (-0.01)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.47 (+0.01), TKMR: 21.45 (-0.22), ARNA: 4.55 (+0.02), DYAX: 15.00 (-0.16), XOMA: 3.41 (-0.01)
InsiderInsights.com Daily Round Up 12/30/14: XOMA, ECR, SNCR, AVK
InsiderInsights - at Seeking Alpha - Wed Dec 31, 10:49AM CST
BDSI: 14.92 (+0.93), ECR: 7.29 (+0.12), KFRC: 23.24 (+0.26), EVDY: 13.80 (-0.32), SAM: 303.26 (-0.97), AERI: 27.91 (+0.14), FUND: 7.47 (+0.05), RFMD: 16.59 (-0.35), AVK: 17.07 (-0.01), SNCR: 43.89 (+1.06), FTEK: 3.31 (+0.01), CAS: 6.14 (-0.01), COB: 10.25 (+0.18), XOMA: 3.41 (-0.01), CRM: 62.85 (+1.59)
XOMA (XOMA) Is Today's Dead Cat Bounce Stock
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a "dead cat bounce" (down big yesterday but up big today) candidate
XOMA: 3.41 (-0.01)
Investors look to Lighten Up on Shares of XOMA, Shares Down 7.3% (XOMA)
Comtex SmarTrend(R) - Tue Dec 23, 11:35AM CST
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 7.3% to $3.67 on 1.1x average daily volume. XOMA has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-6.4% to the Dow's 0.5%) and underperformed the S&P 500 (-6.4% to the S&P's 0.2%) during today's trading.
XOMA: 3.41 (-0.01)
Acne Vulgaris - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/86w8nv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Advancell - Allergan - AndroScience - AntiCancer - Ausio Pharmaceuticals - Biomar Microbial - Boehringer Ingelheim - Braintree Laboratories - Celtaxsys - Cosmo Pharmaceuticals - Cutanea Life Sciences - Delenex Therapeutics - Deltanoid Pharmaceuticals - Dermira - ELORAC - Ensoltek - Foamix - Galderma - GlaxoSmithKline - Kasiak Research - Maruho - OrigImm - Phosphagenics - Photocure - Provectus Biopharmaceuticals - RestorGenex Corporation - Thesan Pharmaceuticals - Toyama Chemical - Valeant Pharmaceuticals International - XBiotech USA - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/86...e_vulgaris
PVCT: 0.79 (-0.02), AGN: 229.49 (+1.87), GSK: 47.94 (+1.99), XOMA: 3.41 (-0.01), VRX.TO: 207.95 (-1.47)
InsiderInsights.com Daily Round Up 12/16/14: XOMA, NS, TEP, RES
InsiderInsights - at Seeking Alpha - Wed Dec 17, 2:27PM CST
RH: 86.77 (-1.55), VRTX: 113.66 (+4.03), RES: 13.36 (+0.93), CCO: 9.46 (+0.07), HDS: 28.62 (+0.24), NS: 61.94 (-0.06), MFRM: 62.22 (-0.12), PCLN: 1,103.37 (+11.42), HERO: 0.92 (+0.02), TEP: 48.97 (+0.52), LC: 21.95 (+0.48), WIW: 11.29 (unch), FII: 35.09 (+0.20), HMTV: 13.25 (+0.23), DYN: 28.39 (+0.01), TWTR: 48.50 (+0.55), FOXF: 16.14 (+0.31), YUM: 74.69 (-0.11), WIA: 11.49 (-0.03), XOMA: 3.41 (-0.01)
Xoma prices offering
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 8:47AM CST
XOMA: 3.41 (-0.01)
XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants
GlobeNewswire - Tue Dec 09, 8:12AM CST
XOMA Corporation (Nasdaq:XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. The shares and warrants will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3. XOMA anticipates its aggregate proceeds from the offering will be approximately $37.7 million, not including any future proceeds from the exercise of the warrants, after deducting the placement agent's discount and estimated offering expenses payable by XOMA. The offering is expected to close on or about December 12, 2014, subject to customary closing conditions.
XOMA: 3.41 (-0.01)
InsiderInsights.com Daily Round Up 12/4/14: GPRO, XOMA, PSEC, KMT
InsiderInsights - at Seeking Alpha - Fri Dec 05, 5:22PM CST
GPRO: 45.27 (-0.02), CLR: 47.36 (+0.74), PATK: 46.96 (+0.45), JONE: 10.18 (+0.18), RL: 135.20 (-0.60), PRSS: 2.95 (-0.08), KMT: 35.44 (+0.86), TSRA: 39.27 (-0.05), WDAY: 91.84 (+0.67), DYN: 28.39 (+0.01), WRLD: 78.79 (-0.21), OC: 38.72 (+0.19), DATA: 99.90 (+1.40), SFXE: 3.49 (+0.01), PSEC: 8.67 (+0.07), REPH: 3.13 (-0.12), XOMA: 3.41 (-0.01)
Strong On High Relative Volume: XOMA (XOMA)
at The Street - Fri Dec 05, 9:05AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a strong on high relative volume candidate
XOMA: 3.41 (-0.01)
XOMA sell-off continues
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 12:30PM CST
XOMA: 3.41 (-0.01)
XOMA Down 6.9%, Shares Slide into the Red (XOMA)
Comtex SmarTrend(R) - Wed Dec 03, 10:07AM CST
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 6.9% to $4.74 on 1.5x average daily volume. XOMA has traded 2.7 million shares thus far today, vs. average volume of 1.8 million shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.1%) and underperformed the S&P 500 (-6.9% to the S&P's 0.2%) during today's trading.
XOMA: 3.41 (-0.01)
